Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin

(2012) D. Devineni et al.   DIABETES OBESITY & METABOLISM

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

(2011) R. Grempler et al.   DIABETES OBESITY & METABOLISM

Role of Chronic and Acute Hyperglycemia in the Development of Diabetes Complications

(2011) M. Loredana Marcovecchio et al.   Diabetes Technology & Therapeutics

Safety, Pharmacokinetic, and Pharmacodynamic Profiles of Ipragliflozin (ASP1941), a Novel and Selective Inhibitor of Sodium-Dependent Glucose Co-Transporter 2, in Patients with Type 2 Diabetes Mellitus

(2011) Sherwyn L. Schwartz et al.   Diabetes Technology & Therapeutics

Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes

(2011) Muhammad A. Abdul-Ghani et al.   ENDOCRINE REVIEWS

Management of diabetes across the course of disease: minimizing obesity-associated complications

(2011) Caroline Apovian   Diabetes Metabolic Syndrome and Obesity-Targets and Therapy

Long-term Effects of a Lifestyle Intervention on Weight and Cardiovascular Risk Factors in Individuals With Type 2 Diabetes Mellitus

(2010)   ARCHIVES OF INTERNAL MEDICINE

Emerging treatment options for type 2 diabetes

(2010) Milan K. Piya et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Standards of Medical Care in Diabetes--2011

(2010)   DIABETES CARE

Dapagliflozin: more than just another oral glucose-lowering agent?

(2010) Niki Katsiki et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies

(2010) The Emerging Risk Factors Collaboration   LANCET

Defining and Achieving Treatment Success in Patients With Type 2 Diabetes Mellitus

(2010) Mark W. Stolar   MAYO CLINIC PROCEEDINGS

Diabetes Prevalence and Therapeutic Target Achievement in the United States, 1999 to 2006

(2009) Bernard M.Y. Cheung et al.   AMERICAN JOURNAL OF MEDICINE

Redefining treatment success in type 2 diabetes mellitus: Comprehensive targeting of core defects

(2009) W. T. CEFALU et al.   CLEVELAND CLINIC JOURNAL OF MEDICINE

Dapagliflozin, a Novel SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

(2009) B Komoroski et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin Sensitizers: Applicability of a novel insulin-independent treatment

(2009) J. P.H. Wilding et al.   DIABETES CARE

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

(2009) J. E. Gerich   DIABETIC MEDICINE

Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implications

(2009) George L. Bakris et al.   KIDNEY INTERNATIONAL

Therapeutic targets to reduce cardiovascular disease in type 2 diabetes

(2009) Cyrus DeSouza et al.   NATURE REVIEWS DRUG DISCOVERY

Prevalence, Treatment, and Control of Diagnosed Diabetes in the U.S. National Health and Nutrition Examination Survey 1999–2004

(2008) Kwok Leung Ong et al.   ANNALS OF EPIDEMIOLOGY

Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

(2008) J. F. List et al.   DIABETES CARE

Effect of a Multifactorial Intervention on Mortality in Type 2 Diabetes

(2008) Peter Gæde et al.   NEW ENGLAND JOURNAL OF MEDICINE